- Home
- MIRA vs BCTX Comparison
MIRA vs BCTX Comparison
Compare MIRA & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | BCTX |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 31.1M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MIRA | BCTX |
|---|---|---|
| Price | $0.83 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.5M | 243.4K |
| Earning Date | 05-13-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $2.60 |
| 52 Week High | $2.45 | $14.68 |
Technical Indicators
Market Signals| Indicator | MIRA | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 65.90 |
| Support Level | $0.72 | $4.10 |
| Resistance Level | $0.82 | $4.38 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 20.47 | 82.41 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.